1、Weinreb RN, Aung T, MedeirosFA. The pathophysiology and treatment
of glaucoma: a review[ J]. JAMA, 2014, 311(18): 1901-1911. DOI:
10.1001/jama.2014.3192.Weinreb RN, Aung T, MedeirosFA. The pathophysiology and treatment
of glaucoma: a review[ J]. JAMA, 2014, 311(18): 1901-1911. DOI:
10.1001/jama.2014.3192.
2、B o u G h a n e m G O, Wa r e h a m L K , C a l k i n s D J. A d d r e s s i n g
neurodegeneration in glaucoma: mechanisms, challenges, and
treatments[ J]. Prog Retin Eye Res, 2024, 100: 101261. DOI: 10.1016/
j.preteyeres.2024.101261.B o u G h a n e m G O, Wa r e h a m L K , C a l k i n s D J. A d d r e s s i n g
neurodegeneration in glaucoma: mechanisms, challenges, and
treatments[ J]. Prog Retin Eye Res, 2024, 100: 101261. DOI: 10.1016/
j.preteyeres.2024.101261.
3、WangYX, Xu L, Yang H, et al. Prevalence of glaucoma in North China:
the Beijing eye study[ J]. Am J Ophthalmol, 2010, 150(6): 917-924.
DOI: 10.1016/j.ajo.2010.06.037.WangYX, Xu L, Yang H, et al. Prevalence of glaucoma in North China:
the Beijing eye study[ J]. Am J Ophthalmol, 2010, 150(6): 917-924.
DOI: 10.1016/j.ajo.2010.06.037.
4、Quigley HA, Broman AT. The number of people with glaucoma
worldwide in 2010 and 2020[ J]. BrJ Ophthalmol, 2006, 90(3): 262-
267. DOI: 10.1136/bjo.2005.081224.Quigley HA, Broman AT. The number of people with glaucoma
worldwide in 2010 and 2020[ J]. BrJ Ophthalmol, 2006, 90(3): 262-
267. DOI: 10.1136/bjo.2005.081224.
5、Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and
projections of glaucoma burden through 2040: a systematic review and
meta-analysis[ J]. Ophthalmology, 2014, 121(11): 2081-2090. DOI:
10.1016/j.ophtha.2014.05.013.Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and
projections of glaucoma burden through 2040: a systematic review and
meta-analysis[ J]. Ophthalmology, 2014, 121(11): 2081-2090. DOI:
10.1016/j.ophtha.2014.05.013.
6、Jayaram H, Kolko M, Friedman DS, et al. Glaucoma: now and
beyond[ J]. Lancet, 2023, 402(10414): 1788-1801. DOI: 10.1016/
S0140-6736(23)01289-8.Jayaram H, Kolko M, Friedman DS, et al. Glaucoma: now and
beyond[ J]. Lancet, 2023, 402(10414): 1788-1801. DOI: 10.1016/
S0140-6736(23)01289-8.
7、Quigley HA, Addicks EM, Green WR , et al. Optic nerve damage
in human glaucoma, II: The site of injury and susceptibility to
damage[ J]. Arch Ophthalmol, 1981, 99(4): 635-649. DOI: 10.1001/
archopht.1981.03930010635009.Quigley HA, Addicks EM, Green WR , et al. Optic nerve damage
in human glaucoma, II: The site of injury and susceptibility to
damage[ J]. Arch Ophthalmol, 1981, 99(4): 635-649. DOI: 10.1001/
archopht.1981.03930010635009.
8、Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in
primary open angle glaucoma[ J]. Surv Ophthalmol, 1994, 39(1): 23-
42. DOI: 10.1016/s0039-6257(05)80042-6.Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in
primary open angle glaucoma[ J]. Surv Ophthalmol, 1994, 39(1): 23-
42. DOI: 10.1016/s0039-6257(05)80042-6.
9、BurgoyneCF, DownsJC, Bellezza AJ, et al. The optic nerve head as a
biomechanical structure: a new paradigm for understanding the role of
IOP-related stress and strain in the pathophysiology of glaucomatous
optic nerve head damage[ J]. Prog Retin Eye Res, 2005, 24(1): 39-73.
DOI: 10.1016/j.preteyeres.2004.06.001.BurgoyneCF, DownsJC, Bellezza AJ, et al. The optic nerve head as a
biomechanical structure: a new paradigm for understanding the role of
IOP-related stress and strain in the pathophysiology of glaucomatous
optic nerve head damage[ J]. Prog Retin Eye Res, 2005, 24(1): 39-73.
DOI: 10.1016/j.preteyeres.2004.06.001.
10、Rieck J. The pathogenesis of glaucoma in the interplay with the immune
system[ J]. Invest Ophthalmol Vis Sci, 2013, 54(3): 2393-2409. DOI:
10.1167/iovs.12-9781.Rieck J. The pathogenesis of glaucoma in the interplay with the immune
system[ J]. Invest Ophthalmol Vis Sci, 2013, 54(3): 2393-2409. DOI:
10.1167/iovs.12-9781.
11、Ju WK, Kim KY, Lindsey JD, et al. Intraocular pressure elevation induces
mitochondrial fission and triggers OPA1 release in glaucomatous optic
nerve[ J]. Invest Ophthalmol Vis Sci, 2008, 49(11): 4903-4911. DOI:
10.1167/iovs.07-1661.Ju WK, Kim KY, Lindsey JD, et al. Intraocular pressure elevation induces
mitochondrial fission and triggers OPA1 release in glaucomatous optic
nerve[ J]. Invest Ophthalmol Vis Sci, 2008, 49(11): 4903-4911. DOI:
10.1167/iovs.07-1661.
12、Quigley HA. The contribution of the sclera and lamina cribrosa to the
pathogenesis of glaucoma: diagnostic and treatment implications[ J].
Prog Brain Res, 2015, 220: 59-86. DOI: 10.1016/bs.pbr.2015.04.003.Quigley HA. The contribution of the sclera and lamina cribrosa to the
pathogenesis of glaucoma: diagnostic and treatment implications[ J].
Prog Brain Res, 2015, 220: 59-86. DOI: 10.1016/bs.pbr.2015.04.003.
13、Almasieh M, Wilson AM, Morquette B, et al. The molecular basis of
retinal ganglion cell death in glaucoma[ J]. Prog Retin Eye Res, 2012, 31(2): 152-181. DOI: 10.1016/j.preteyeres.2011.11.002.Almasieh M, Wilson AM, Morquette B, et al. The molecular basis of
retinal ganglion cell death in glaucoma[ J]. Prog Retin Eye Res, 2012, 31(2): 152-181. DOI: 10.1016/j.preteyeres.2011.11.002.
14、Quigley HA, McKinnon SJ, Zack DJ, et al. Retrograde axonal transport
of BDNF in retinal ganglion cells is blocked by acute IOP elevation in
rats[ J]. Invest Ophthalmol Vis Sci, 2000, 41(11): 3460-3466.Quigley HA, McKinnon SJ, Zack DJ, et al. Retrograde axonal transport
of BDNF in retinal ganglion cells is blocked by acute IOP elevation in
rats[ J]. Invest Ophthalmol Vis Sci, 2000, 41(11): 3460-3466.
15、Ren R, Jonas JB, Tian G, et al. Cerebrospinal fluid pressure in glaucoma:
a prospective study[ J]. Ophthalmology, 2010, 117(2): 259-266. DOI:
10.1016/j.ophtha.2009.06.058.Ren R, Jonas JB, Tian G, et al. Cerebrospinal fluid pressure in glaucoma:
a prospective study[ J]. Ophthalmology, 2010, 117(2): 259-266. DOI:
10.1016/j.ophtha.2009.06.058.
16、Flammer J, Orgül S, Costa VP, et al. The impact of ocular blood flow
in glaucoma[ J]. Prog Retin Eye Res, 2002, 21(4): 359-393. DOI:
10.1016/s1350-9462(02)00008-3.Flammer J, Orgül S, Costa VP, et al. The impact of ocular blood flow
in glaucoma[ J]. Prog Retin Eye Res, 2002, 21(4): 359-393. DOI:
10.1016/s1350-9462(02)00008-3.
17、Caprioli J, Coleman AL,Blood Flow in glaucoma discussion. Blood
pressure, perfusion pressure, and glaucoma[ J]. AmJ Ophthalmol, 2010,
149(5): 704-712. DOI: 10.1016/j.ajo.2010.01.018.Caprioli J, Coleman AL,Blood Flow in glaucoma discussion. Blood
pressure, perfusion pressure, and glaucoma[ J]. AmJ Ophthalmol, 2010,
149(5): 704-712. DOI: 10.1016/j.ajo.2010.01.018.
18、Kiyota N, Shiga Y, Omodaka K, et al. Time-course changes in optic
nerve head blood flow and retinal nerve fiber layer thickness in eyes
with open-angle glaucoma[ J]. Ophthalmology, 2021, 128(5): 663-671.
DOI: 10.1016/j.ophtha.2020.10.010.Kiyota N, Shiga Y, Omodaka K, et al. Time-course changes in optic
nerve head blood flow and retinal nerve fiber layer thickness in eyes
with open-angle glaucoma[ J]. Ophthalmology, 2021, 128(5): 663-671.
DOI: 10.1016/j.ophtha.2020.10.010.
19、Grunwald JE, Sinclair SH, Riva CE. Autoregulation of the retinal
circulation in response to decrease of intraocular pressure below
normal[ J]. Invest Ophthalmol Vis Sci, 1982, 23(1): 124-127.Grunwald JE, Sinclair SH, Riva CE. Autoregulation of the retinal
circulation in response to decrease of intraocular pressure below
normal[ J]. Invest Ophthalmol Vis Sci, 1982, 23(1): 124-127.
20、Alarcon-Martinez L, Shiga Y, Villafranca-Baughman D, et al. Pericyte
dysfunction and loss of interpericyte tunneling nanotubes promote
neurovascular deficits in glaucoma[ J]. ProcNatlAcadSciUSA, 2022,
119(7): e2110329119. DOI: 10.1073/pnas.2110329119.Alarcon-Martinez L, Shiga Y, Villafranca-Baughman D, et al. Pericyte
dysfunction and loss of interpericyte tunneling nanotubes promote
neurovascular deficits in glaucoma[ J]. ProcNatlAcadSciUSA, 2022,
119(7): e2110329119. DOI: 10.1073/pnas.2110329119.
21、Wareham LK, Calkins DJ. The neurovascular unit in glaucomatous
neurodegeneration[ J]. Front Cell Dev Biol, 2020, 8: 452. DOI:
10.3389/fcell.2020.00452.Wareham LK, Calkins DJ. The neurovascular unit in glaucomatous
neurodegeneration[ J]. Front Cell Dev Biol, 2020, 8: 452. DOI:
10.3389/fcell.2020.00452.
22、Casson RJ, Chidlow G, Crowston JG, et al. Retinal energy metabolism
in health and glaucoma[ J]. Prog Retin Eye Res, 2021, 81: 100881.
DOI: 10.1016/j.preteyeres.2020.100881.Casson RJ, Chidlow G, Crowston JG, et al. Retinal energy metabolism
in health and glaucoma[ J]. Prog Retin Eye Res, 2021, 81: 100881.
DOI: 10.1016/j.preteyeres.2020.100881.
23、Dixon A, ShimMS, Nettesheim A, et al. Autophagy deficiency protects
against ocular hypertension and neurodegeneration in experimental
and spontanous glaucoma mouse models[ J]. Cell Death Dis, 2023,
14(8): 554. DOI: 10.1038/s41419-023-06086-3.Dixon A, ShimMS, Nettesheim A, et al. Autophagy deficiency protects
against ocular hypertension and neurodegeneration in experimental
and spontanous glaucoma mouse models[ J]. Cell Death Dis, 2023,
14(8): 554. DOI: 10.1038/s41419-023-06086-3.
24、Jassim AH , Inman DM , Mitchell CH . C r o s s t a l k b e t w e e n
dysfunctional mitochondria and inflammation in glaucomatous
neurodegeneration[ J]. Front Pharmacol, 2021, 12: 699623. DOI:
10.3389/fphar.2021.699623.Jassim AH , Inman DM , Mitchell CH . C r o s s t a l k b e t w e e n
dysfunctional mitochondria and inflammation in glaucomatous
neurodegeneration[ J]. Front Pharmacol, 2021, 12: 699623. DOI:
10.3389/fphar.2021.699623.
25、Tezel G. Immune regulation toward immunomodulation for
neuroprotection in glaucoma[ J]. Curr Opin Pharmacol, 2013, 13(1):
23-31. DOI: 10.1016/j.coph.2012.09.013.Tezel G. Immune regulation toward immunomodulation for
neuroprotection in glaucoma[ J]. Curr Opin Pharmacol, 2013, 13(1):
23-31. DOI: 10.1016/j.coph.2012.09.013.
26、Mazumder AG, Julé AM, Sun D. Astrocytes of the optic nerve exhibit a
region-specific and temporally distinct response to elevated intraocular
pressure[ J]. Mol Neurodegener, 2023, 18(1): 68. DOI: 10.1186/
s13024-023-00658-9.Mazumder AG, Julé AM, Sun D. Astrocytes of the optic nerve exhibit a
region-specific and temporally distinct response to elevated intraocular
pressure[ J]. Mol Neurodegener, 2023, 18(1): 68. DOI: 10.1186/
s13024-023-00658-9.
27、Tribble JR , Harder JM, Williams PA , et al. Ocular hypertension
suppresses homeostatic gene expression in optic nerve head microglia
of DBA/2 J mice[ J]. Mol Brain, 2020, 13(1): 81. DOI: 10.1186/
s13041-020-00603-7.Tribble JR , Harder JM, Williams PA , et al. Ocular hypertension
suppresses homeostatic gene expression in optic nerve head microglia
of DBA/2 J mice[ J]. Mol Brain, 2020, 13(1): 81. DOI: 10.1186/
s13041-020-00603-7.
28、O ' C a l l a g h a n J, D e l a n e y C , O ' C o n n o r M , e t a l . M a t r i x
metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma[ J].
Sci Adv, 2023, 9(16): eadf6537. DOI: 10.1126/sciadv.adf6537.O ' C a l l a g h a n J, D e l a n e y C , O ' C o n n o r M , e t a l . M a t r i x
metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma[ J].
Sci Adv, 2023, 9(16): eadf6537. DOI: 10.1126/sciadv.adf6537.
29、Wu J, Bell OH, Copland DA, et al. Gene therapy for glaucoma by ciliary
body aquaporin 1 disruption using CRISPR-Cas9[ J]. Mol Ther, 2020,
28(3): 820-829. DOI: 10.1016/j.ymthe.2019.12.012.Wu J, Bell OH, Copland DA, et al. Gene therapy for glaucoma by ciliary
body aquaporin 1 disruption using CRISPR-Cas9[ J]. Mol Ther, 2020,
28(3): 820-829. DOI: 10.1016/j.ymthe.2019.12.012.
30、Jiang J, Kong K, Fang X, et al. CRISPR-Cas9-mediated deletion of
carbonic anhydrase 2 in the ciliary body to treat glaucoma[ J]. Cell Rep
Med, 2024, 5(5): 101524. DOI: 10.1016/j.xcrm.2024.101524.Jiang J, Kong K, Fang X, et al. CRISPR-Cas9-mediated deletion of
carbonic anhydrase 2 in the ciliary body to treat glaucoma[ J]. Cell Rep
Med, 2024, 5(5): 101524. DOI: 10.1016/j.xcrm.2024.101524.
31、Ferrari MP, Mantelli F, Sacchetti M, et al. Safety and pharmacokinetics
of escalating doses of human recombinant nerve growth factor eye
drops in a double-masked, randomized clinical trial[ J]. Bio Drugs,
2014, 28(3): 275-283. DOI: 10.1007/s40259-013-0079-5.Ferrari MP, Mantelli F, Sacchetti M, et al. Safety and pharmacokinetics
of escalating doses of human recombinant nerve growth factor eye
drops in a double-masked, randomized clinical trial[ J]. Bio Drugs,
2014, 28(3): 275-283. DOI: 10.1007/s40259-013-0079-5.
32、Oddone F, Roberti G, Micera A, et al. Exploring serum levels of brain
derived neurotrophic factor and nerve growth factor across glaucoma
stages[ J]. PLoS One, 2017, 12(1): e0168565. DOI: 10.1371/journal.
pone.0168565.Oddone F, Roberti G, Micera A, et al. Exploring serum levels of brain
derived neurotrophic factor and nerve growth factor across glaucoma
stages[ J]. PLoS One, 2017, 12(1): e0168565. DOI: 10.1371/journal.
pone.0168565.
33、Krishnan A, Kocab AJ, Zacks DN, et al. A small peptide antagonist
of the Fas receptor inhibits neuroinflammation and prevents axon
degeneration and retinal ganglion cell death in an inducible mouse
model of glaucoma[ J]. J Neuroinflammation, 2019, 16(1): 184. DOI:
10.1186/s12974-019-1576-3.Krishnan A, Kocab AJ, Zacks DN, et al. A small peptide antagonist
of the Fas receptor inhibits neuroinflammation and prevents axon
degeneration and retinal ganglion cell death in an inducible mouse
model of glaucoma[ J]. J Neuroinflammation, 2019, 16(1): 184. DOI:
10.1186/s12974-019-1576-3.
34、Sun Y, Wirta D, Murahashi W, et al. Safety and target engagement of
complement C1q inhibitor ANX007 in neurodegenerative eye disease:
results from phase I studies in glaucoma[ J]. Ophthalmol Sci, 2023,
3(2): 100290. DOI: 10.1016/j.xops.2023.100290.Sun Y, Wirta D, Murahashi W, et al. Safety and target engagement of
complement C1q inhibitor ANX007 in neurodegenerative eye disease:
results from phase I studies in glaucoma[ J]. Ophthalmol Sci, 2023,
3(2): 100290. DOI: 10.1016/j.xops.2023.100290.
35、Vergroesen JE, Thee EF, Ahmadizar F, et al. A ssociation of
diabetes medication w ith open-angle glaucoma, age-related
macular degeneration, and cataract in the Rotterdam study[ J].
JAMA Ophthalmol, 2022, 140(7): 674-681. DOI: 10.1001/
jamaophthalmol.2022.1435.Vergroesen JE, Thee EF, Ahmadizar F, et al. A ssociation of
diabetes medication w ith open-angle glaucoma, age-related
macular degeneration, and cataract in the Rotterdam study[ J].
JAMA Ophthalmol, 2022, 140(7): 674-681. DOI: 10.1001/
jamaophthalmol.2022.1435.
36、Zhao WQ, Chen H, Quon MJ, et al. Insulin and the insulin receptor in
experimental models of learning and memory[ J]. Eur J Pharmacol,
2004, 490(1-3): 71-81. DOI: 10.1016/j.ejphar.2004.02.045.Zhao WQ, Chen H, Quon MJ, et al. Insulin and the insulin receptor in
experimental models of learning and memory[ J]. Eur J Pharmacol,
2004, 490(1-3): 71-81. DOI: 10.1016/j.ejphar.2004.02.045.
37、Kouassi Nzoughet J, Chaodela Barca JM, Guehlouz K , et al.
Nicotinamide deficiency in primary open-angle glaucoma[ J]. Invest
Ophthalmol Vis Sci, 2019, 60(7): 2509-2514. DOI: 10.1167/iovs.19-
27099.Kouassi Nzoughet J, Chaodela Barca JM, Guehlouz K , et al.
Nicotinamide deficiency in primary open-angle glaucoma[ J]. Invest
Ophthalmol Vis Sci, 2019, 60(7): 2509-2514. DOI: 10.1167/iovs.19-
27099.
38、Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of
nicotinamide for skin-cancer chemoprevention[ J]. N Engl J Med,
2015, 373(17): 1618-1626. DOI: 10.1056/NEJMoa1506197.Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of
nicotinamide for skin-cancer chemoprevention[ J]. N Engl J Med,
2015, 373(17): 1618-1626. DOI: 10.1056/NEJMoa1506197.
39、Hui F, Tang J, Williams PA, et al. Improvement in inner retinal function
in glaucoma with nicotinamide (vitamin B3) supplementation: a
crossover randomized clinical trial[ J]. Clin Exp Ophthalmol, 2020,
48(7): 903-914. DOI: 10.1111/ceo.13818.Hui F, Tang J, Williams PA, et al. Improvement in inner retinal function
in glaucoma with nicotinamide (vitamin B3) supplementation: a
crossover randomized clinical trial[ J]. Clin Exp Ophthalmol, 2020,
48(7): 903-914. DOI: 10.1111/ceo.13818.
40、Kumar A, Ou Y. From bench to behaviour: the role of lifestyle factors
on intraocular pressure, neuroprotection, and disease progression in
glaucoma[ J]. Clin Exp Ophthalmol, 2023, 51(4): 380-394. DOI:
10.1111/ceo.14218.Kumar A, Ou Y. From bench to behaviour: the role of lifestyle factors
on intraocular pressure, neuroprotection, and disease progression in
glaucoma[ J]. Clin Exp Ophthalmol, 2023, 51(4): 380-394. DOI:
10.1111/ceo.14218.